$246 Million is the total value of Iguana Healthcare Management, LLC's 82 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHPG | New | SHIRE PLCsponsored adr | $11,045,000 | – | 60,000 | +100.0% | 4.49% | – |
| ANTM | New | ANTHEM INC | $9,194,000 | – | 70,000 | +100.0% | 3.74% | – |
| New | ALEXION PHARMACEUTICALS INCcall | $5,838,000 | – | 50,000 | +100.0% | 2.38% | – | |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $5,838,000 | – | 50,000 | +100.0% | 2.38% | – |
| New | MEDICINES COcall | $4,708,000 | – | 140,000 | +100.0% | 1.92% | – | |
| New | LILLY ELI & COput | $3,908,000 | – | 50,000 | +100.0% | 1.59% | – | |
| ILMN | New | ILLUMINA INC | $3,510,000 | – | 25,000 | +100.0% | 1.43% | – |
| New | CIGNA CORPORATIONcall | $3,200,000 | – | 25,000 | +100.0% | 1.30% | – | |
| New | ABBVIE INCcall | $3,096,000 | – | 50,000 | +100.0% | 1.26% | – | |
| ONCE | New | SPARK THERAPEUTICS INC | $3,068,000 | – | 60,000 | +100.0% | 1.25% | – |
| KTWO | New | K2M GROUP HLDGS INC | $2,173,000 | – | 140,000 | +100.0% | 0.88% | – |
| EPZM | New | EPIZYME INC | $2,048,000 | – | 200,000 | +100.0% | 0.83% | – |
| MGNX | New | MACROGENICS INC | $2,024,000 | – | 75,000 | +100.0% | 0.82% | – |
| MDCO | New | MEDICINES CO | $2,018,000 | – | 60,000 | +100.0% | 0.82% | – |
| XENT | New | INTERSECT ENT INC | $1,940,000 | – | 150,000 | +100.0% | 0.79% | – |
| BIOS | New | BIOSCRIP INC | $1,913,000 | – | 750,000 | +100.0% | 0.78% | – |
| New | RADIUS HEALTH INCput | $1,838,000 | – | 50,000 | +100.0% | 0.75% | – | |
| RDUS | New | RADIUS HEALTH INC | $1,838,000 | – | 50,000 | +100.0% | 0.75% | – |
| UNH | New | UNITEDHEALTH GROUP INC | $1,765,000 | – | 12,500 | +100.0% | 0.72% | – |
| New | WELLCARE HEALTH PLANS INCput | $1,609,000 | – | 15,000 | +100.0% | 0.66% | – | |
| PMC | New | PHARMERICA CORP | $1,603,000 | – | 65,000 | +100.0% | 0.65% | – |
| MRUS | New | MERUS N V | $1,598,000 | – | 200,000 | +100.0% | 0.65% | – |
| New | SAGE THERAPEUTICS INCcall | $1,507,000 | – | 50,000 | +100.0% | 0.61% | – | |
| MCRB | New | SERES THERAPEUTICS INC | $1,453,000 | – | 50,000 | +100.0% | 0.59% | – |
| New | ALNYLAM PHARMACEUTICALS INCcall | $1,387,000 | – | 25,000 | +100.0% | 0.56% | – | |
| RVNC | New | REVANCE THERAPEUTICS INC | $1,360,000 | – | 100,000 | +100.0% | 0.55% | – |
| ALKS | New | ALKERMES PLC | $1,297,000 | – | 30,000 | +100.0% | 0.53% | – |
| NERV | New | MINERVA NEUROSCIENCES INC | $1,276,000 | – | 125,000 | +100.0% | 0.52% | – |
| WBA | New | WALGREENS BOOTS ALLIANCE INC | $1,249,000 | – | 15,000 | +100.0% | 0.51% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $1,235,000 | – | 90,000 | +100.0% | 0.50% | – |
| MYL | New | MYLAN N V | $1,081,000 | – | 25,000 | +100.0% | 0.44% | – |
| FLML | New | FLAMEL TECHNOLOGIES SAsponsored adr | $806,000 | – | 75,000 | +100.0% | 0.33% | – |
| ADMA | New | ADMA BIOLOGICS INC | $744,000 | – | 125,000 | +100.0% | 0.30% | – |
| New | SERES THERAPEUTICS INCput | $726,000 | – | 25,000 | +100.0% | 0.30% | – | |
| CCXI | New | CHEMOCENTRYX INC | $674,000 | – | 150,000 | +100.0% | 0.27% | – |
| CLSD | New | CLEARSIDE BIOMEDICAL INC | $526,000 | – | 75,015 | +100.0% | 0.21% | – |
| IMMU | New | IMMUNOMEDICS INC | $522,000 | – | 225,000 | +100.0% | 0.21% | – |
| New | EXELIXIS INCcall | $391,000 | – | 50,000 | +100.0% | 0.16% | – | |
| New | NOVAVAX INCput | $364,000 | – | 50,000 | +100.0% | 0.15% | – | |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $335,000 | – | 150,000 | +100.0% | 0.14% | – |
| New | RIGEL PHARMACEUTICALS INCcall | $112,000 | – | 50,000 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-11-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.